← Browse by Condition
Medical Condition
agitation
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3
NCT06808984 Phase 2
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Enrollment
120 pts
Location
United States
Sponsor
Celgene
NCT06937229 Phase 3
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Enrollment
600 pts
Location
United States, Argen...
Sponsor
Bristol-Myers Squibb